Fulgent Genetics beats Q2 revenue estimates

Fulgent Genetics

01/08/2025 12:09

Overview

Fulgent reports Q2 2025 total revenus of $81.8 million, beating analyst expectations

Adjusted EPS for Q2 beats consensus, despite GAAP loss of $19 mln

Co repurchased 130,000 shares, reflecting confidence in business strategy

Outlook

Fulgent expects 2025 core revenue of approximately $320 mln

Company projects 2025 GAAP loss of $2.10 per share

Fulgent anticipates 2025 non-GAAP loss of $0.35 per share

Company expects cash and investments of $770 mln by year-end

Result Drivers

LABORATORY SERVICES - Growth attributed to progress in Laboratory Services business

THERAPEUTIC DEVELOPMENT - Advancements in clinical trials for Therapeutic Development business

RAISED GUIDANCE - Increased full-year core revenue guidance to $320 mln, reflecting positive momentum

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$81.80 mln
$76.20 mln (3 Analysts)
Q2 Core Revenue
$81.70 mln
Q2 Adjusted EPS
Beat
$0.07
-$0.18 (3 Analysts)
Q2 Adjusted EBITDA
Beat
-$3 mln
-$7.60 mln (2 Analysts)
Q2 Pretax Profit
Miss
-$21.52 mln
-$5.75 mln (2 Analysts)
Q2 Gross Profit
$34.44 mln
Q2 Operating Expenses
$54.15 mln
Q2 Operating Income
-$19.71 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Fulgent Genetics Inc is $23.00, about 25.3% above its July 31 closing price of $17.18

Press Release: ID:nBw59k9Kla

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)